Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirilumab + Nivolumab +/- Ipilimumab in Advanced Solid Tumors
NCT01714739Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2012
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, triple-blind trial of lirilumab in solid tumor and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events up to 2.5 years, Number of Participants With Serious Adverse Events up to 2.5 years and 3 more. Started Oct 2012; status: completed.
02
Drugs
lirilumab
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01714739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01714739.